Sequential use of bevacizumab and cetuximab in patients with K-RAS wild type advanced colorectal cancer.

e14681 Background: Monoclonal antibodies targeting either VEGF or EGFR have improved the treatment outcomes in patients with advanced colorectal cancer (CRC). Although cetuximab or panitumumab are ...